Pierre Benite

• A study to investigate the clinical benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone in adults with newl … Ended recruitment
  2024-514417-34-00 5 2017-12-14 Cancer
• A Study to Assess Safety, Effectiveness, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Patients with Paroxys … Ended recruitment
  2023-506287-14-00 7 2017-04-21 Paroxysmal nocturnal hemoglobinuria (PNH)
• Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapy Ended recruitment
  2024-513972-16-00 5 2017-01-30 - Resected tumors of sinuses or salivary glands - Non-operable tumors
• PIO2STOP_Combination study of Pioglitazone and Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia patients after failure of a TKI … Ended recruitment
  2024-515460-31-00 4 2016-11-07 CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA
• A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL … Ended recruitment
  2024-515846-18-00 7 2016-09-19 Newly diagnosed Diffuse Large B Cell Lymphoma
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient … Ended recruitment
  2024-518741-21-00 4 2014-12-23 colon cancer
• A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Ended recruitment
  2024-517622-25-00 5 2013-12-06 Patients with localized prostate cancer and high-risk features of rela
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment
  2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
• Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended recruitment
  2024-515171-35-00 5 2011-07-06 Prostatic adenocarnicoma with high risk of recurrence
• IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficac … Halted
  2024-517254-99-00 4 2025-09-16 The patients enrolled in IMMUNORARE will be adult patients with 5 rar
• Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy in women with advanced ovarian cancer Halted
  2024-515996-37-00 3 2021-07-30 peritoneal carcinosis of ovarian origin cancer
• A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL Halted
  2023-506136-32-00 9 2020-10-12 Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (
• Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase … Halted
  2024-513576-18-00 5 2020-07-17 Cervical Cancer
• Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, immunogenicity and safety of one dose of … Ended
  2024-520354-37-00 4 2025-09-08 Influenza disease
• Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection Ended
  2024-519856-94-00 4 2025-08-18 Cystic fibrosis
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom … Ended
  2024-512848-30-00 4 2024-11-12 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
• Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin … Ended
  2024-516435-27-00 4 2024-11-05 High-risk myeloïd malignancies
• SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended
  2024-513648-27-00 4 2024-10-25 Patients with newly or active diffuse Systemic sclerosis (SSc) at the
• [68Ga]Ga-PentixaFor-PET imaging for staging of marginal zone lymphoma Ended
  2022-500918-25-00 5 2024-05-20 Marginal Zone Lymphoma
• A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Pat … Ended
  2023-506976-28-00 9 2024-05-16 Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
• A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis Ended
  2022-502647-35-00 4 2023-09-01 Non-alcoholic steatohepatitis
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line met … Ended
  2023-506385-30-00 9 2023-05-22 Advanced Urothelial Carcinoma

Showing 337–360 of 404 trials